Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Celebrates Simponi Approval With Schering – For Now

This article was originally published in The Pink Sheet Daily

Executive Summary

As Schering waits to see if partner J&J will challenge Merck merger, FDA clears once-monthly follow-on to Remicade.
Advertisement

Related Content

Remicade: A Study In Translational Looping
NICE Gives Thumbs Down to Simponi--For Now
NICE Gives Thumbs Down to Simponi--For Now
Schering/J&J's Simponi Gets Positive EU Nod For Approval; J&J Seeks Full Rights To Drug
J&J To Seek Remicade Rights Amid Pending Schering-Plough/Merck Merger
Just-Approved Cimzia Set To Enter Tough RA Market
Schering Looks Ahead To Simponi Launch In Canada, Europe After Sluggish Q1
Will Johnson & Johnson Undercut Merck’s Bid to Buy Schering-Plough?
Will Johnson & Johnson Undercut Merck’s Bid to Buy Schering-Plough?
Medarex Pipeline Hearty As Investors Focus On Dicey Melanoma Bid

Topics

Advertisement
UsernamePublicRestriction

Register

PS069335

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel